SCHEMBL1491759

SCHEMBL1491759

CP(C)(=O)c1ccc(N)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
ACHE P22303 1/20 0.41
HPGD P15428 1/20 0.40
CYP3A4 P08684 5/20 0.38
TDP1 Q9NUW8 5/20 0.38
ALDH1A1 P00352 5/20 0.38
TP53 P04637 2/20 0.38
MAPK1 P28482 3/20 0.36
ALOX15 P16050 3/20 0.36
TSHR P16473 2/20 0.36
TXNRD1 Q16881 1/20 0.36
TXNRD3 Q86VQ6 1/20 0.36
TXNRD2 Q9NNW7 1/20 0.36
LMNA P02545 1/20 0.36
MPO P05164 1/20 0.36
CYP2C9 P11712 1/20 0.36
HTR6 P50406 1/20 0.36
FDPS P14324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5664202 0.97 MAPT (0.42) MEN1MAPTKMT2AACHEHPGD
SCHEMBL141747 0.83 HPGD (0.59) MEN1MAPTKMT2AACHEHPGD
SCHEMBL15534249 0.79 FDPS (0.42) MEN1MAPTKMT2AACHEHPGD
SCHEMBL3289719 0.77 CYP3A4 (0.50) MEN1MAPTKMT2AACHECYP3A4
SCHEMBL24899757 0.74 HPGD (0.42) HPGDTSHRLMNACA1CA2
SCHEMBL3888438 0.74 HPGD (0.70) MEN1MAPTKMT2AACHEHPGD
SCHEMBL11232452 0.74 TYR (0.44) MEN1MAPTKMT2AHPGDALDH1A1
SCHEMBL22348417 0.73 MAP4K4 (0.42) MAPTCYP3A4TDP1ALDH1A1TP53
SCHEMBL22352641 0.73 MAOA (0.55) MEN1CYP3A4CA12CA1CA2
SCHEMBL21313336 0.72 ALDH1A1 (0.36) CYP3A4ALDH1A1TSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103887-A1 PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 北京康辰药业股份有限公司 2026-05-21 WO disclosed
EP-4676602-A1 COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF Merck Sharp & Dohme LLC (US) 2026-01-14 EP disclosed
WO-2025092989-A1 SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF 泰州红云制药有限公司 2025-05-08 WO disclosed
WO-2024240242-A1 COMPOUND CONTAINING AMIDE-SUBSTITUTED AROMATIC RING, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 正大天晴药业集团股份有限公司 2024-11-28 WO disclosed
EP-2300013-B2 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2024-11-13 EP disclosed
WO-2024187153-A1 COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-09-12 WO disclosed
CN-114315899-B 3- (Aromatic ring imidazole) pyrazolopyrimidine derivative and application thereof 上海美迪西生物医药股份有限公司 2024-09-03 CN disclosed
WO-2022213975-A1 COMPOUNDS TARGETING Y220C MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-10-13 WO disclosed
CN-114315899-A 3- (aromatic benzimidazolyl) pyrazolopyrimidine derivative and application thereof 上海美迪西生物医药股份有限公司 2022-04-12 CN disclosed
CN-112004790-A Novel indoleamine 2, 3-dioxygenase inhibitor and preparation method and application thereof 信达生物制药(苏州)有限公司 2020-11-27 CN disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
EP-1940843-A2 UNSATURATED HETEROCYCLIC DERIVATIVES ARIAD PHARMACEUTICALS, INC. (US) 2008-07-09 EP disclosed
WO-2008046216-A1 KINASE INHIBITORS AND USES THEREOF METHYLGENE, INC. (CA) 2008-04-24 WO disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed
WO-2007021937-A2 UNSATURATED HETEROCYCLIC DERIVATIVES ARIAD PHARMACEUTICALS, INC. (US) 2007-02-22 WO disclosed
EP-1487459-A4 PEPTIDE ANALOGUES AND USES THEREOF ARIAD PHARMA INC (US) 2006-05-24 EP disclosed
US-20050065171-A1 Substituted purine derivatives ARIAD PHARMACEUTICALS, INC. 2005-03-24 US disclosed
EP-1487459-A1 PEPTIDE ANALOGUES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2004-12-22 EP disclosed
WO-2003077928-A1 PEPTIDE ANALOGUES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2003-09-25 WO disclosed
WO-2003077928-A1 PEPTIDE ANALOGUES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065171-A1 Substituted purine derivatives ADORA2A, PNP, HPRT1 MEN1 3230/4885MAPT 4360/4885KMT2A 2802/4885
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF ABL1, MAP3K20, MAP3K1 MEN1 1165/4885MAPT 1229/4885KMT2A 811/4885
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds TYMP, PNP, PIKFYVE MEN1 4347/4885MAPT 2025/4885KMT2A 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.